SUMAYA BIOTECH

Our lead product, SUM-101 (SumayaVac1), successfully completed a first-in-human clinical trial in 2019, demonstrating safety and immunogenicity. SUM-101 is an innovative malaria vaccine based on the recombinant, full-length merozoite surface protein 1 (MSP1). SumayaVac1 is expected to target both the asymptomatic liver stages and the blood stages of the human malaria parasite Plasmodium falciparum, by eliciting both a humoral and cellular immune response. A safety, immunogenicity and efficacy trial in Tanzania is about to be launched... In 2021, Sumaya Biotech's approach was validated by the EU Malaria Fund, who selected Sumaya Biotech as one of 8 companies to receive funding... Our third development project is a small molecule intended for the treatment of severe malaria. SUM-201 (SC83288) has a completely new mechanism of action, making it a most interesting candidate for second line treatment in the face of increasing resistances against other Malaria therapeutics.

Also known as: Sumaya Biotech GmbH & Co. KG

Primary location: Heidelberg Germany